Swift Biosciences

The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.

The sample prep technologies firm intends to use the funding to expand its commercial channels, among other things.

A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.

The partners plan to improve yields from small input samples and provide better sequencing libraries.

Both partners believe the agreement will help expand the scope of their services and give them additional markets for their products.  

The companies will combine their technologies to create workflows for the next-generation sequencing of tumor cells obtained from FFPE samples. 

Pages

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.